vs

Side-by-side financial comparison of Claros Mortgage Trust, Inc. (CMTG) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $46.7M, roughly 1.8× Claros Mortgage Trust, Inc.). PROCEPT BioRobotics Corp runs the higher net margin — -38.1% vs -468.9%, a 430.9% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -22.4%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs -10.9%).

Claros Mortgage Trust, Inc. is a U.S.-based real estate investment trust that invests in diversified mortgage-related assets, including residential and commercial mortgage loans and mortgage-backed securities. It pursues stable, risk-adjusted long-term returns for shareholders via rigorous asset evaluation and active portfolio management.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

CMTG vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.8× larger
PRCT
$83.1M
$46.7M
CMTG
Growing faster (revenue YoY)
PRCT
PRCT
+42.6% gap
PRCT
20.2%
-22.4%
CMTG
Higher net margin
PRCT
PRCT
430.9% more per $
PRCT
-38.1%
-468.9%
CMTG
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
-10.9%
CMTG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CMTG
CMTG
PRCT
PRCT
Revenue
$46.7M
$83.1M
Net Profit
$-219.2M
$-31.6M
Gross Margin
64.9%
Operating Margin
-4.1%
Net Margin
-468.9%
-38.1%
Revenue YoY
-22.4%
20.2%
Net Profit YoY
-117.7%
-27.9%
EPS (diluted)
$-1.56
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMTG
CMTG
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$46.7M
$76.4M
Q3 25
$46.1M
$83.3M
Q2 25
$51.6M
$79.2M
Q1 25
$43.4M
$69.2M
Q4 24
$60.2M
$68.2M
Q3 24
$64.9M
$58.4M
Q2 24
$64.5M
$53.4M
Net Profit
CMTG
CMTG
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-219.2M
$-29.8M
Q3 25
$-9.5M
$-21.4M
Q2 25
$-181.7M
$-19.6M
Q1 25
$-78.6M
$-24.7M
Q4 24
$-100.7M
$-18.9M
Q3 24
$-56.2M
$-21.0M
Q2 24
$-11.6M
$-25.6M
Gross Margin
CMTG
CMTG
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
CMTG
CMTG
PRCT
PRCT
Q1 26
-4.1%
Q4 25
-40.6%
Q3 25
-27.8%
Q2 25
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
-50.3%
Net Margin
CMTG
CMTG
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-468.9%
-39.1%
Q3 25
-20.7%
-25.7%
Q2 25
-351.9%
-24.7%
Q1 25
-181.3%
-35.8%
Q4 24
-167.2%
-27.6%
Q3 24
-86.7%
-35.9%
Q2 24
-17.9%
-48.0%
EPS (diluted)
CMTG
CMTG
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$-1.56
$-0.54
Q3 25
$-0.07
$-0.38
Q2 25
$-1.30
$-0.35
Q1 25
$-0.56
$-0.45
Q4 24
$-0.72
$-0.34
Q3 24
$-0.40
$-0.40
Q2 24
$-0.09
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMTG
CMTG
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$173.2M
$245.6M
Total DebtLower is stronger
$3.2B
$51.7M
Stockholders' EquityBook value
$1.5B
$347.7M
Total Assets
$4.7B
$487.1M
Debt / EquityLower = less leverage
2.06×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMTG
CMTG
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$173.2M
$286.5M
Q3 25
$339.5M
$294.3M
Q2 25
$209.2M
$302.7M
Q1 25
$127.8M
$316.2M
Q4 24
$99.1M
$333.7M
Q3 24
$113.9M
$196.8M
Q2 24
$148.2M
$214.1M
Total Debt
CMTG
CMTG
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$3.2B
$51.6M
Q3 25
$3.7B
$51.6M
Q2 25
$4.0B
$51.5M
Q1 25
$4.7B
$51.5M
Q4 24
$4.9B
$51.5M
Q3 24
$5.1B
$51.4M
Q2 24
$5.3B
$51.4M
Stockholders' Equity
CMTG
CMTG
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$1.5B
$365.9M
Q3 25
$1.7B
$380.3M
Q2 25
$1.8B
$385.8M
Q1 25
$1.9B
$389.2M
Q4 24
$2.0B
$402.2M
Q3 24
$2.1B
$241.2M
Q2 24
$2.2B
$251.8M
Total Assets
CMTG
CMTG
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$4.7B
$508.1M
Q3 25
$5.4B
$511.5M
Q2 25
$5.8B
$513.1M
Q1 25
$6.7B
$519.4M
Q4 24
$7.0B
$534.0M
Q3 24
$7.3B
$374.1M
Q2 24
$7.6B
$374.4M
Debt / Equity
CMTG
CMTG
PRCT
PRCT
Q1 26
0.15×
Q4 25
2.06×
0.14×
Q3 25
2.09×
0.14×
Q2 25
2.29×
0.13×
Q1 25
2.42×
0.13×
Q4 24
2.44×
0.13×
Q3 24
2.44×
0.21×
Q2 24
2.46×
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMTG
CMTG
PRCT
PRCT
Operating Cash FlowLast quarter
$-30.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMTG
CMTG
PRCT
PRCT
Q1 26
Q4 25
$-30.5M
$-10.3M
Q3 25
$8.8M
$-6.6M
Q2 25
$-5.8M
$-15.0M
Q1 25
$-35.8M
$-17.0M
Q4 24
$84.5M
$-32.4M
Q3 24
$39.2M
$-18.8M
Q2 24
$5.5M
$-15.7M
Free Cash Flow
CMTG
CMTG
PRCT
PRCT
Q1 26
Q4 25
$-12.2M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
CMTG
CMTG
PRCT
PRCT
Q1 26
Q4 25
-15.9%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
CMTG
CMTG
PRCT
PRCT
Q1 26
Q4 25
2.4%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMTG
CMTG

Real Estate Owned Portfolio$34.2M73%
Other$11.1M24%
Mixed Use Property Fixed Rents$1.4M3%

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons